An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers

Interleukin (IL)-21 is an attractive antitumor agent with potent immunomodulatory functions. Yet thus far, the cytokine has yielded only partial responses in solid cancer patients, and conditions for beneficial IL-21 immunotherapy remain elusive. The current work aims to identify clinically-relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Elishmereni, Moran, Kheifetz, Yuri, Søndergaard, Henrik, Overgaard, Rune Viig, Agur, Zvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182868/
https://www.ncbi.nlm.nih.gov/pubmed/22022259
http://dx.doi.org/10.1371/journal.pcbi.1002206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182868/
https://www.ncbi.nlm.nih.gov/pubmed/22022259
http://dx.doi.org/10.1371/journal.pcbi.1002206

Ejemplares similares